Titus Ball Sells 136 Shares of BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) insider Titus Ball sold 136 shares of the business’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $271.33, for a total value of $36,900.88. Following the sale, the insider owned 36 shares in the company, valued at approximately $9,767.88. This trade represents a 79.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

BeOne Medicines Stock Performance

NASDAQ:ONC opened at $260.27 on Friday. The stock has a market cap of $28.56 billion, a P/E ratio of 58.23 and a beta of 0.49. The company has a current ratio of 3.64, a quick ratio of 3.27 and a debt-to-equity ratio of 0.20. The stock’s 50-day moving average is $300.30 and its 200-day moving average is $314.98. BeOne Medicines Ltd. – Sponsored ADR has a 1-year low of $239.25 and a 1-year high of $385.22.

BeOne Medicines (NASDAQ:ONC) last released its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. The company had revenue of $1.51 billion for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. Equities research analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 earnings per share for the current year.

Hedge Funds Weigh In On BeOne Medicines

Hedge funds and other institutional investors have recently made changes to their positions in the stock. EFG International AG acquired a new position in shares of BeOne Medicines in the fourth quarter worth approximately $25,000. Leonteq Securities AG acquired a new position in shares of BeOne Medicines in the fourth quarter worth approximately $35,000. Daiwa Securities Group Inc. acquired a new position in shares of BeOne Medicines in the second quarter worth approximately $35,000. CWM LLC lifted its stake in shares of BeOne Medicines by 32.8% in the fourth quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after acquiring an additional 39 shares during the period. Finally, Group One Trading LLC acquired a new position in BeOne Medicines in the fourth quarter valued at approximately $61,000. 48.55% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ONC has been the topic of several research reports. Guggenheim boosted their price target on BeOne Medicines from $410.00 to $420.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Royal Bank Of Canada boosted their price target on BeOne Medicines from $425.00 to $436.00 and gave the stock an “outperform” rating in a report on Tuesday, June 2nd. Wall Street Zen upgraded BeOne Medicines from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Barclays lifted their price objective on BeOne Medicines from $405.00 to $409.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $395.00 price objective on shares of BeOne Medicines in a research note on Thursday, May 7th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $390.00.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.